EHR-Integrated CGM Decision Support Trial Targets Insulin-Treated Type 2 Diabetes in Primary Care

References

1. 1.Ajjan, R. A., Cummings, M. H., Jennings, P., Leelarathna, L., Rayman, G., & Wilmot, E. G. (2018). Optimising use of rate of change trend arrows for insulin dosing decisions in type 1 diabetes. Diabetes Technology & Therapeutics, 20(8), 531-540. https://doi.org/10.1089/dia.2018.0095
2. 2.American Diabetes Association Professional Practice Committee. (2024). 7. Diabetes technology: Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1), S126-S144. https://doi.org/10.2337/dc24-S007
3. 3.Australian Institute of Health and Welfare. (2023). Diabetes in Australia. AIHW. https://www.aihw.gov.au/reports/diabetes/diabetes-in-australia
4. 4.Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., ... & Phillip, M. (2019). Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 42(8), 1593-1603. https://doi.org/10.2337/dci19-0028
5. 5.Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019). The relationships between time in range, hyperglycemia metrics, and HbA1c. Journal of Diabetes Science and Technology, 13(4), 614-626. https://doi.org/10.1177/1932296818822496
6. 6.Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., ... & Aleppo, G. (2018). Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care, 41(11), 2275-2280. https://doi.org/10.2337/dc18-1581
7. 7.Bright, T. J., Wong, A., Dhurjati, R., Bristow, E., Bastian, L., Coeytaux, R. R., ... & Lobach, D. (2012). Effect of clinical decision-support systems: a systematic review. Annals of Internal Medicine, 157(1), 29-43. https://doi.org/10.7326/0003-4819-157-1-201207030-00450
8. 8.Curran, G. M., Bauer, M., Mittman, B., Pyne, J. M., & Stetler, C. (2012). Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Medical Care, 50(3), 217-226. https://doi.org/10.1097/MLR.0b013e3182408812
9. 9.HealthPartners Institute. (2024). Translating Continuous Glucose Monitoring (CGM) Data Into Action to Improve Management of Insulin-Treated T2D in Primary Care. ClinicalTrials.gov. NCT07394075. https://clinicaltrials.gov/study/NCT07394075
10. 10.Polonsky, W. H., Hessler, D., Ruedy, K. J., & Beck, R. W. (2017). The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care, 40(6), 736-741. https://doi.org/10.2337/dc17-0133
11. 11.Therapeutic Goods Administration. (2024). Continuous glucose monitoring systems. Australian Government Department of Health. https://www.tga.gov.au/products/medical-devices/medical-device-types/continuous-glucose-monitoring-systems